Clinical trial
Study of Rivoglitazone in Type 2 Diabetes Mellitus
NCT00484198 · Daiichi Sankyo, Industry · Completed
Key facts
| NCT number | NCT00484198 |
|---|---|
| Title | Study of Rivoglitazone in Type 2 Diabetes Mellitus |
| Official title | A Randomized, Double-blind, Placebo and Active Comparator-Controlled, Parallel-Group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus |
| Lead sponsor | Daiichi Sankyo, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Pioglitazone, Placebo, Rivoglitazone |
| Enrollment | 1,912 |
| Start date | Apr 23, 2007 |
| Primary completion | Feb 12, 2009 |
| Completion | Feb 12, 2009 |
| First posted | Jun 8, 2007 |
| Last update posted | Jul 27, 2021 |
| Countries | Argentina, Austria, Chile, Czechia, Germany, Hungary, India, Latvia, Mexico, Peru, Puerto Rico, Romania and 6 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: